VolitionRX Stock to Reverse Split on Tuesday, April 28th (NYSEAMERICAN:VNRX)

VolitionRX Limited (NYSEAMERICAN:VNRX) shares are going to reverse split before the market opens on Tuesday, April 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

VolitionRX Price Performance

VNRX opened at $0.14 on Friday. The business has a 50 day simple moving average of $0.19 and a 200-day simple moving average of $0.29. The stock has a market capitalization of $22.82 million, a P/E ratio of -0.65 and a beta of 1.33. VolitionRX has a 12 month low of $0.14 and a 12 month high of $0.94.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.71 million. Research analysts anticipate that VolitionRX will post -0.11 EPS for the current year.

Wall Street Analysts Forecast Growth

VNRX has been the subject of several recent analyst reports. Citigroup cut VolitionRX to a “hold” rating in a report on Monday. HC Wainwright reduced their price target on VolitionRX from $1.50 to $1.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Finally, D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $2.33.

Hedge Funds Weigh In On VolitionRX

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Lagoda Investment Management L.P. raised its holdings in VolitionRX by 6.7% during the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after purchasing an additional 782,000 shares during the last quarter. Armistice Capital LLC raised its holdings in VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the last quarter. Geode Capital Management LLC raised its holdings in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares during the last quarter. Citadel Advisors LLC raised its holdings in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in VolitionRX during the fourth quarter worth $34,000. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.